Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06354868
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-12
First Post:
2024-04-03
Brief Title:
A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication ASM Efficacy
Sponsor:
Neuronostics Ltd
Organization:
Neuronostics Ltd
Study Overview
Official Title:
A Prospective Observational Clinical Study to Investigate the Relationship Between Seizure Frequency and BioEP During ASM Titration in Newly Diagnosed Patients With Epilepsy and to Assess the Utility of BioEP as an Early Prognostic Indicator of Anti-seizure Medication ASM Efficacy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ECLIPSE
Brief Summary:
This multisite prospective clinical study is to investigate the relationship between seizure type and frequency with the BioEP result during ASM titration in newly diagnosed patients with epilepsy and to assess the utility of BioEP as an early prognostic indicator of ASM efficacy
Detailed Description:
The study will consist of a cohort of adult patients who present to first seizure clinics The patients will have had an EEG performed as part of the clinical care pathway this will act as their baseline reference BioEP value They will also have received an epilepsy diagnosis and will be due to start ASM titration as part of their epilepsy treatment One stop clinics shall be targeted primarily for their same day EEGs service to allow a baseline EEG to be obtained prior to the patient starting ASMs in those who get an EEG diagnosis on the same day
Patients who have initially seen a Neurologist in a first seizure clinic and are under a period of watchful waiting and then return to the clinic a second time and receive an epilepsy diagnosis will be eligible to enter the trial The second encounter with Neurology would usually be due to the occurrence of a second seizure or by a positive EEG being recorded as part of their usual care during the watch and wait period and the clinician deciding to start ASMS on that basis The study will utilise their 1st EEG performed as the baseline EEG provided this is performed within a 12-month window prior to their second Neurology encounter and during a period of no ASMs
A baseline BioEP result shall be gathered from baseline EEG data prior to commencement of the ASM titration regime and a set of computational biomarkers BioEP shall be identified from relevant EEG segments free of IEDs In addition to the clinical care pathway participants will also receive additional routine EEGs at 1 3 and 6 and 12 months after commencing treatment The EEGs performed at 1 3 6 and 12 months duration shall also have their BioEP results identified at these specified time points
Any patient who requires a ASM medication change during the first 6 months of the trial an additional EEG will be collected at 9 months and then again at the usual 12 months time point
Patients who have initially seen a Neurologist in a first seizure clinic and are under a period of watchful waiting and then return to the clinic a second time and receive an epilepsy diagnosis will be eligible to enter the trial The second encounter with Neurology would usually be due to the occurrence of a second seizure or by a positive EEG being recorded as part of their usual care during the watch and wait period and the clinician deciding to start ASMS on that basis The study will utilise their 1st EEG performed as the baseline EEG provided this is performed within a 12-month window prior to their second Neurology encounter and during a period of no ASMs
A baseline BioEP result shall be gathered from baseline EEG data prior to commencement of the ASM titration regime and a set of computational biomarkers BioEP shall be identified from relevant EEG segments free of IEDs In addition to the clinical care pathway participants will also receive additional routine EEGs at 1 3 and 6 and 12 months after commencing treatment The EEGs performed at 1 3 6 and 12 months duration shall also have their BioEP results identified at these specified time points
Any patient who requires a ASM medication change during the first 6 months of the trial an additional EEG will be collected at 9 months and then again at the usual 12 months time point
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None